{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T20:00:41Z","timestamp":1770580841548,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hhmd, LLC"},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Equine recurrent uveitis (ERU) is a painful and debilitating autoimmune disease and represents the only spontaneous model of human recurrent uveitis (RU). Despite the efficacy of existing treatments, RU remains a leading cause of visual handicap in horses and humans. Cytokines, which utilize Janus kinase 2 (Jak2) for signaling, drive the inflammatory processes in ERU that promote blindness. Notably, suppressor of cytokine signaling 1 (SOCS1), which naturally limits the activation of Jak2 through binding interactions, is often deficient in autoimmune disease patients. <jats:italic>Significantly,<\/jats:italic> we previously showed that topical administration of a SOCS1 peptide mimic (SOCS1-KIR) mitigated induced rodent uveitis. In this pilot study, we test the potential to translate the therapeutic efficacy observed in experimental rodent uveitis to equine patient disease. Through bioinformatics and peptide binding assays we demonstrate putative binding of the SOCS1-KIR peptide to equine Jak2. We also show that topical, or intravitreal injection of SOCS1-KIR was well tolerated within the equine eye through physical and ophthalmic examinations. Finally, we show that topical SOCS1-KIR administration was associated with significant clinical ERU improvement. Together, these results provide a scientific rationale, and supporting experimental evidence for the therapeutic use of a SOCS1 mimetic peptide in RU.<\/jats:p>","DOI":"10.1038\/s41598-022-11338-x","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T13:04:07Z","timestamp":1651583047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide"],"prefix":"10.1038","volume":"12","author":[{"given":"Caryn E.","family":"Plummer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Polk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghyo Sarah","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amari","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Wilhelmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Devin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Clay Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan D.","family":"Kolaczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"11338_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609855","author":"RL Degroote","year":"2021","unstructured":"Degroote, R. L. & Deeg, C. A. Immunological insights in equine recurrent uveitis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.609855 (2021).","journal-title":"Front. Immunol."},{"key":"11338_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cveq.2004.04.010","volume":"20","author":"BC Gilger","year":"2004","unstructured":"Gilger, B. C. & Michau, T. M. Equine recurrent uveitis: New methods of management. Vet. Clin. N. Am. Equine Pract. 20, 417\u2013427 (2004).","journal-title":"Vet. Clin. N. Am. Equine Pract."},{"key":"11338_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0749-0739(17)30441-8","volume":"8","author":"KL Schwink","year":"1992","unstructured":"Schwink, K. L. Equine uveitis. Vet. Clin. N. Am. Equine Pract. 8, 557\u2013574 (1992).","journal-title":"Vet. Clin. N. Am. Equine Pract."},{"key":"11338_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.2042-3306.2010.tb05636.x","volume":"42","author":"BC Gilger","year":"2010","unstructured":"Gilger, B. C. Equine recurrent uveitis: The viewpoint from the USA. Equine Vet. J. 42, 57\u201361 (2010).","journal-title":"Equine Vet. J."},{"key":"11338_CR5","first-page":"1","volume":"2016","author":"C He","year":"2016","unstructured":"He, C. et al. SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis). Mediators Inflamm. 2016, 1\u201315 (2016).","journal-title":"Mediators Inflamm."},{"key":"11338_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/archopht.1994.01090170052021","volume":"112","author":"MJ Taravella","year":"1994","unstructured":"Taravella, M. J. et al. Calcific band keratopathy associated with the use of topical steroid-phosphate preparations. Arch. Ophthalmol. 112, 608 (1994).","journal-title":"Arch. Ophthalmol."},{"key":"11338_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","volume":"111","author":"DC Gritz","year":"2004","unstructured":"Gritz, D. C. & Wong, I. G. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology 111, 491\u2013500 (2004).","journal-title":"Ophthalmology"},{"key":"11338_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1463-5224.2011.00951.x","volume":"15","author":"DP Regan","year":"2012","unstructured":"Regan, D. P. et al. Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis. Vet. Ophthalmol. 15, 145\u2013152 (2012).","journal-title":"Vet. Ophthalmol."},{"key":"11338_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0165-2427(99)00082-3","volume":"71","author":"BC Gilger","year":"1999","unstructured":"Gilger, B. C. et al. Characterization of T-lymphocytes in the anterior uvea of eyes with chronic equine recurrent uveitis. Vet. Immunol. Immunopathol. 71, 17\u201328 (1999).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"11338_CR10","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.4049\/jimmunol.180.9.6070","volume":"180","author":"X Liu","year":"2008","unstructured":"Liu, X., Lee, Y. S., Yu, C.-R. & Egwuagu, C. E. Loss of STAT3 in CD4 + T cells prevents development of experimental autoimmune diseases. J. Immunol. 180, 6070\u20136076 (2008).","journal-title":"J. Immunol."},{"key":"11338_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1084\/jem.20071258","volume":"205","author":"D Luger","year":"2008","unstructured":"Luger, D. et al. Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799\u2013810 (2008).","journal-title":"J. Exp. Med."},{"key":"11338_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","volume":"13","author":"A Amadi-Obi","year":"2007","unstructured":"Amadi-Obi, A. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1. Nat. Med. 13, 711\u2013718 (2007).","journal-title":"Nat. Med."},{"key":"11338_CR13","doi-asserted-by":"publisher","first-page":"e71619","DOI":"10.1371\/journal.pone.0071619","volume":"8","author":"M Kulbrock","year":"2013","unstructured":"Kulbrock, M., Lehner, S., Metzger, J., Ohnesorge, B. & Distl, O. A genome-wide association study identifies risk loci to equine recurrent uveitis in German warmblood horses. PLoS ONE 8, e71619 (2013).","journal-title":"PLoS ONE"},{"key":"11338_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S68595","author":"P Lin","year":"2015","unstructured":"Lin, P. Targeting interleukin-6 for noninfectious uveitis. Clin. Ophthalmol. https:\/\/doi.org\/10.2147\/OPTH.S68595 (2015).","journal-title":"Clin. Ophthalmol."},{"key":"11338_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1471-4892(03)00070-5","volume":"3","author":"K Inagaki-Ohara","year":"2003","unstructured":"Inagaki-Ohara, K., Hanada, T. & Yoshimura, A. Negative regulation of cytokine signaling and inflammatory diseases. Curr. Opin. Pharmacol. 3, 435\u2013442 (2003).","journal-title":"Curr. Opin. Pharmacol."},{"key":"11338_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dci.2014.02.009","volume":"45","author":"A Skjesol","year":"2014","unstructured":"Skjesol, A. et al. Functional conservation of suppressors of cytokine signaling proteins between teleosts and mammals: Atlantic salmon SOCS1 binds to JAK\/STAT family members and suppresses type I and II IFN signaling. Dev. Comp. Immunol. 45, 177\u2013189 (2014).","journal-title":"Dev. Comp. Immunol."},{"key":"11338_CR17","doi-asserted-by":"publisher","first-page":"6978","DOI":"10.1167\/iovs.11-7688","volume":"52","author":"C-R Yu","year":"2011","unstructured":"Yu, C.-R. et al. Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation. Investig. Opthalmol. Vis. Sci. 52, 6978 (2011).","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"11338_CR18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.746164","author":"SM McCormick","year":"2016","unstructured":"McCormick, S. M., Gowda, N., Fang, J. X. & Heller, N. M. Suppressor of cytokine signaling (SOCS)1 regulates interleukin-4 (IL-4)-activated insulin receptor substrate (IRS)-2 tyrosine phosphorylation in monocytes and macrophages via the proteasome. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.M116.746164 (2016).","journal-title":"J. Biol. Chem."},{"key":"11338_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jneuroim.2014.05.013","volume":"273","author":"V Sede\u00f1o-Monge","year":"2014","unstructured":"Sede\u00f1o-Monge, V. et al. Quantitative analysis of the suppressors of cytokine signaling 1 and 3 in peripheral blood leukocytes of patients with multiple sclerosis. J. Neuroimmunol. 273, 117\u2013119 (2014).","journal-title":"J. Neuroimmunol."},{"key":"11338_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/sji.12475","volume":"84","author":"B Sukka-Ganesh","year":"2016","unstructured":"Sukka-Ganesh, B. & Larkin, J. Therapeutic potential for targeting the suppressor of cytokine signalling-1 pathway for the treatment of SLE. Scand. J. Immunol. 84, 299\u2013309 (2016).","journal-title":"Scand. J. Immunol."},{"key":"11338_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00324","author":"J Sharma","year":"2019","unstructured":"Sharma, J. & Larkin, J. Therapeutic implication of SOCS1 modulation in the treatment of autoimmunity and cancer. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00324 (2019).","journal-title":"Front. Pharmacol."},{"key":"11338_CR22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003819","author":"EL Collins","year":"2011","unstructured":"Collins, E. L. et al. Inhibition of SOCS1 \u2212\/\u2212 Lethal autoinflammatory disease correlated to enhanced peripheral Foxp3 + regulatory T cell homeostasis. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.1003819 (2011).","journal-title":"J. Immunol."},{"key":"11338_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2010.10.018","volume":"232","author":"LD Jager","year":"2011","unstructured":"Jager, L. D. et al. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis. J. Neuroimmunol. 232, 108\u2013118 (2011).","journal-title":"J. Neuroimmunol."},{"key":"11338_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86017-4","author":"J Sharma","year":"2021","unstructured":"Sharma, J. et al. Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL\/lpr mouse autoimmune model. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-021-86017-4 (2021).","journal-title":"Sci. Rep."},{"key":"11338_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2015.05.011","volume":"62","author":"C He","year":"2015","unstructured":"He, C. et al. Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis. J. Autoimmun. 62, 31\u201338 (2015).","journal-title":"J. Autoimmun."},{"key":"11338_CR26","doi-asserted-by":"publisher","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","volume":"44","author":"NA O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation. Nucl. Acids Res. 44, D733\u2013D745 (2016).","journal-title":"Nucl. Acids Res."},{"key":"11338_CR27","doi-asserted-by":"publisher","first-page":"10881","DOI":"10.1093\/nar\/16.22.10881","volume":"16","author":"F Corpet","year":"1988","unstructured":"Corpet, F. Multiple sequence alignment with hierarchical clustering. Nucl. Acids Res. 16, 10881\u201310890 (1988).","journal-title":"Nucl. Acids Res."},{"key":"11338_CR28","doi-asserted-by":"crossref","unstructured":"Procter, J. B. et al. Alignment of Biological Sequences with Jalview. in Methods in Molecular Biology, Vol. 2231 (2021).","DOI":"10.1007\/978-1-0716-1036-7_18"},{"key":"11338_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","volume":"25","author":"AM Waterhouse","year":"2009","unstructured":"Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J. Jalview Version 2-A multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189\u20131191 (2009).","journal-title":"Bioinformatics"},{"key":"11338_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: A sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."},{"key":"11338_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn180","author":"A Dereeper","year":"2008","unstructured":"Dereeper, A. et al. Phylogeny. fr: Robust phylogenetic analysis for the non-specialist. Nucl. Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkn180 (2008).","journal-title":"Nucl. Acids Res."},{"key":"11338_CR32","unstructured":"Rambaut, A. FigTree, a graphical viewer of phylogenetic trees. Institute of Evolutionary Biology University of Edinburgh (2009)."},{"key":"11338_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.3","author":"B Webb","year":"2016","unstructured":"Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protocols Bioinform. https:\/\/doi.org\/10.1002\/cpbi.3 (2016).","journal-title":"Curr. Protocols Bioinform."},{"key":"11338_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/bbrc.1998.8077","volume":"243","author":"MM Green","year":"1998","unstructured":"Green, M. M., Larkin, J., Subramaniam, P. S., Szente, B. E. & Johnson, H. M. Human IFN\u03b3 receptor cytoplasmic domain: Expression and interaction with HuIFN\u03b3. Biochem. Biophys. Res. Commun. 243, 170\u2013176 (1998).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"11338_CR35","first-page":"139","volume":"4","author":"TP McDonald","year":"1977","unstructured":"McDonald, T. P. & Shadduck, R. K. Eye irritation. Mod. Adv. Toxicol. 4, 139\u2013191 (1977).","journal-title":"Mod. Adv. Toxicol."},{"key":"11338_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403\u2013410. https:\/\/doi.org\/10.1016\/S0022-2836(05)80360-2 (1990).","journal-title":"J. Mol. Biol."},{"key":"11338_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00469","author":"J Larkin","year":"2013","unstructured":"Larkin, J., Ahmed, C. M., Wilson, T. D. & Johnson, H. M. Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2013.00469 (2013).","journal-title":"Front. Immunol."},{"key":"11338_CR38","doi-asserted-by":"publisher","first-page":"e24134","DOI":"10.4161\/jkst.24134","volume":"2","author":"CE Egwuagu","year":"2013","unstructured":"Egwuagu, C. E. & Larkin, J. III. Therapeutic targeting of STAT pathways in CNS autoimmune diseases. JAK-STAT 2, e24134 (2013).","journal-title":"JAK-STAT"},{"key":"11338_CR39","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.4049\/jimmunol.178.8.5058","volume":"178","author":"LW Waiboci","year":"2007","unstructured":"Waiboci, L. W. et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: Implications for the development of a SOCS-1 antagonist. J. Immunol. 178, 5058\u20135068 (2007).","journal-title":"J. Immunol."},{"key":"11338_CR40","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau, N. P. D. et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat. Commun. 9, 1558 (2018).","journal-title":"Nat. Commun."},{"key":"11338_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1042\/BJ20111647","volume":"443","author":"N Doti","year":"2012","unstructured":"Doti, N. et al. New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries. Biochem. J. 443, 231\u2013240 (2012).","journal-title":"Biochem. J."},{"key":"11338_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00183","author":"CMI Ahmed","year":"2015","unstructured":"Ahmed, C. M. I., Larkin, J. & Johnson, H. M. SOCS1 mimetics and antagonists: A complementary approach to positive and negative regulation of immune function. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00183 (2015).","journal-title":"Front. Immunol."},{"key":"11338_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ceo.13511","volume":"47","author":"M Hassan","year":"2019","unstructured":"Hassan, M. et al. New therapies in development for the management of non-infectious uveitis: A review. Clin. Exp. Ophthalmol. 47, 396\u2013417 (2019).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"11338_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"R-X Wang","year":"2014","unstructured":"Wang, R.-X. et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20, 633\u2013641 (2014).","journal-title":"Nat. Med."},{"key":"11338_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00358","author":"M Bonacini","year":"2020","unstructured":"Bonacini, M. et al. Cytokine profiling in aqueous humor samples from patients with non-infectious uveitis associated with systemic inflammatory diseases. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00358 (2020).","journal-title":"Front. Immunol."},{"key":"11338_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.vetimm.2016.09.008","volume":"182","author":"E Curto","year":"2016","unstructured":"Curto, E., Messenger, K. M., Salmon, J. H. & Gilger, B. C. Cytokine and chemokine profiles of aqueous humor and serum in horses with uveitis measured using multiplex bead immunoassay analysis. Vet. Immunol. Immunopathol. 182, 43\u201351 (2016).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"11338_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tvjl.2015.06.017","volume":"206","author":"F Malalana","year":"2015","unstructured":"Malalana, F., Stylianides, A. & McGowan, C. Equine recurrent uveitis: Human and equine perspectives. Vet. J. 206, 22\u201329 (2015).","journal-title":"Vet. J."},{"key":"11338_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/vop.12704","volume":"23","author":"LK Saldinger","year":"2020","unstructured":"Saldinger, L. K. et al. Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro. Vet. Ophthalmol. 23, 160\u2013170 (2020).","journal-title":"Vet. Ophthalmol."},{"key":"11338_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2939370","author":"C He","year":"2016","unstructured":"He, C. et al. SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis). Mediators Inflamm. https:\/\/doi.org\/10.1155\/2016\/2939370 (2016).","journal-title":"Mediators Inflamm."},{"key":"11338_CR50","doi-asserted-by":"publisher","first-page":"986789","DOI":"10.1155\/2013\/986789","volume":"2013","author":"SK Bedoya","year":"2013","unstructured":"Bedoya, S. K., Lam, B., Lau, K. & Larkin, J. Th17 cells in immunity and autoimmunity. Clin. Dev. Immunol. 2013, 986789 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"11338_CR51","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1167\/iovs.16-19787","volume":"57","author":"KJH Kleinwort","year":"2016","unstructured":"Kleinwort, K. J. H. et al. Immunological characterization of intraocular lymphoid follicles in a spontaneous recurrent uveitis model. Investig. Ophthalmol. Vis. Sci. 57, 4504 (2016).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"11338_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/030098589803500606","volume":"35","author":"A Romeike","year":"1998","unstructured":"Romeike, A., Br\u00fcgmann, M. & Drommer, W. Immunohistochemical studies in equine recurrent uveitis (ERU). Vet. Pathol. 35, 515\u2013526 (1998).","journal-title":"Vet. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11338-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:21:33Z","timestamp":1669342893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11338-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11338"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11338-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"11 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent is currently pending on the SOCS mimetic technology and the research was supported, in part, by a company currently licensing the technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7177"}}